Saturday, April 18, 2026
Search

Corporate Finance & Risk Management

3 articles

Novakand Pharma faces regulatory capital hurdle in SVF Vaccines RTO

Novakand Pharma faces regulatory capital hurdle in SVF Vaccines RTO

Novakand Pharma AB's reverse takeover of SVF Vaccines exposes the Nasdaq First North Premier-listed entity to stringent EMA and FDA compliance requirements. The deal carries catastrophic regulatory risk with medium likelihood, particularly around clinical trial protocols and manufacturing standards. Post-merger capital reserves must cover multi-year approval cycles and potential compliance gaps.

ViaNews Editorial Team (Finance)